A recent ZoomRx survey found that many pharmaceutical and biotech companies prohibit the use of ChatGPT. Endpoints News’ Beth Snyder Bulik reported on April 17 that “Half of pharma and biotech companies restrict its use, but that jumps to 65 percent when narrowed down to the top 20 pharma companies.”
This study surveyed 211 workers from the pharmaceutical and biotech industries with varied job titles and experience with Artificial Intelligence (AI). The employees polled expressed concerns over security when using AI tools. Along with pharmaceutical and biotech businesses, other tech companies like Apple and Microsoft have banned ChatGPT for internal use.
The reasons cited for the possibility of using AI were cost savings and enhanced efficiency. However, “Some 80 percent of those surveyed believe AI is currently overrated, and only 25 percent use ChatGPT more than once a week,” Snyder Bulik wrote.
“You can imagine a scenario where an employee working with ChatGPT enters some proprietary clinical data or maybe sensitive information collected in a conversation with a colleague. But that action inadvertently adds that information and that data into Open AI’s data training set,” ZoomRx’s product manager Andrew Yukawa said in a statement.
